ImmuCell Q2 product sales rise 11.5% on strong US demand

ImmuCell Corporation

ImmuCell Corporation

ICCC

0.00


Overview

  • Animal health biologics firm's preliminary Q2 product sales rose 11.5% yr/yr

  • Growth driven by 27.7% increase in domestic sales, while international sales declined 38.9%

  • Company cites robust U.S. demand and improved product availability for sales increase


Outlook

  • Company did not provide specific guidance for future quarters or full-year results


Result Drivers

  • DOMESTIC SALES SURGE - Co said 27.7% increase in domestic sales drove overall Q2 growth

  • PRODUCT AVAILABILITY - Management cited excellent product availability as supporting strong sales

  • COMMERCIAL EFFORTS - Targeting year-round, price-sensitive dairy customers and expanding commercial team contributed to growth in Dual-Force and Tri-Shield sales


Company press release: ID:nGNX1ZmM4M


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Product Sales

$7.20 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.